Abstract: Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, disodium salt, or its hydrates. Also described is a pharmaceutical composition containing said disodium salt in a pharmaceutically acceptable excipient.

Abstract: Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical doage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.

Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.

Abstract: Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.

Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.

Abstract: Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.

Abstract: Polymorphic forms of the angiotensin II receptor antagonist, 3-?2'-(N-benzoyl)sulfonamidobiphenyl-4-yl!methyl-5,7-dimethyl-2-ethyl-3H-i midazo?4,5-b!pyridine and a method for the preparation of these crystal forms.

Abstract: Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.

Abstract: Crystalline and amorphous insoluble calcium salts of bisphosphonic acids may be formulated to provide compositions suitable for I.M. (intramuscular) and S.C. (subcutaneous) administration. As compared to solutions of the soluble salts of bisphosphonic acids, suspensions of the crystalline and amorphous calcium salts provide slow systemic release of the bisphosphonic acid and reduce tissue damage and localized pain and irritation when used in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.

Abstract: A novel salt of amiloride particularly amiloride citrate has been discovered. Because of its inherent insolubility and less bitter taste, it would lend itself to be more easily formulated into oral liquids, sustained release formulations and chewable tablets than would amiloride hydrochloride.